The team at DropGenie uses digital microfluidics to perform gene editing screens on small numbers of patient cells, accelerating the discovery of new drugs.
Insights from the AD/PD meeting, continued fallout from the FDA layoffs, hope for GLP-1 drugs in Alzheimer’s disease, and more led industry news this week.